[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627417":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":20,"locations":26,"responsibleParty":42,"collaborators":7,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":7,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":7,"maxAge":7,"enrollmentInfo":54,"targetDuration":57,"studyType":58,"phases":7,"briefSummary":59,"conditions":60,"keywords":67,"overallStatus":71,"whyStopped":7,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Caja Costarricense de Seguro Social","OTHER_GOV",null,[9,13,15,17],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Abrocitinib","This registry specifically focuses on patients with moderate-to-severe atopic dermatitis receiving systemic immunosuppressive or biologic therapies in real-world clinical practice in Costa Rica. Unlike clinical trials or other dermatologic registries, this study captures routine-care treatment patterns, including conventional systemic agents and newer targeted biologics used according to physician judgment without protocol-mandated interventions. The registry uniquely characterizes disease severity, treatment response, and quality-of-life outcomes in the Costa Rican population across multiple centers, enabling evaluation of effectiveness, safety, and persistence of advanced therapies in everyday practice rather than controlled research settings.",{"type":10,"name":14,"description":12,"armGroupLabels":7,"otherNames":7},"Upadacitinib",{"type":10,"name":16,"description":12,"armGroupLabels":7,"otherNames":7},"Baricitinib",{"type":18,"name":19,"description":12,"armGroupLabels":7,"otherNames":7},"BIOLOGICAL","Dupilumab",[21],{"name":22,"role":23,"phone":24,"phoneExt":7,"email":25},"Daniel E Barquero-Orias, Dermatologist","CONTACT","+506 83411026","debarque@ccss.sa.cr",[27],{"facility":28,"status":7,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Caja Costarricense del Seguro Social","San José","Provincia de San José","40901","Costa Rica","CR",{"type":35,"coordinates":36},"Point",[37,38],-84.08489,9.93388,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":24,"phoneExt":7,"email":25},{"type":43,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Daniel Barquero Orias","Principal Investigator","100627417","atopic-dermatitis-treated-with-dupilumab-and-jak-inhibitors-in-costa-rica-100627417",false,"NCT07448363","Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","National Registry of Patients With Atopic Dermatitis Under Treatment With Dupilumab and JAK Inhibitors Within the Costa Rican Social Security System","Inclusion Criteria:\n\n* Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria\n* Moderate-to-severe disease requiring systemic or advanced therapy\n* Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care\n* Evaluated in participating dermatology centers in Costa Rica\n* Available clinical records with baseline and follow-up information\n\nExclusion Criteria:\n\n* Lack of sufficient clinical data for severity or treatment assessment","ALL",{"count":55,"type":56},50,"ESTIMATED","5 Years","OBSERVATIONAL","The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:\n\nWhat are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?\n\nWhat treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?\n\nParticipants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.",[61,62,63,64,65,66],"Atopic Dermatitis","Atopic Dermatitis (AD)","Atopic Dermatitis (Eczema)","Atopic Dermatitis Patients","Atopic Dermatitis \u002F Eczema","Atopic Dermatitis, Unspecified",[68,19,11,14,69,70,16],"Registry","JAK-inhibitor","Atopic dermatitis","NOT_YET_RECRUITING","2026-04-02",{"date":74,"type":75},"2026-04-08","ACTUAL",{"date":77,"type":56},"2026-05",{"date":79,"type":56},"2031-05",{"name":5,"class":6},1]